JPMorgan upgraded Novo Nordisk (NYSE: NVO) from Underweight to Neutral.Analyst Richard Vosser comments "our continuing concerns over the long-term growth ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE